Pharmacological treatment of attention-deficit/hyperactivity disorder in adults;Traitement pharmacologique du trouble déficit de l'attention avec hyperactivité de l'adulte

Revue Medicale Suisse

Volumn 4, Issue 165, 2008, Pages 1638-1643

  Rollini, Marc ^a   Baud, Patrick ^b  

^a HUG   (Switzerland)

^b HUG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; MEDIKINET; METHYLPHENIDATE; MODAFINIL; PEMOLINE; PLACEBO; PSYCHOSTIMULANT AGENT;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; HUMAN; LIVER TOXICITY; PERSONALITY DISORDER; PREVALENCE; REVIEW; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; PREVALENCE; SWITZERLAND; TREATMENT OUTCOME;

EID: 48349132376     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Mannuzza S, Klein RG, Moulton JL. Persistence of attention-deficit/ hyperactivity disorder into adulthood : What have we learned from the prospective follow-up studies ? J Atten Disord 2003;7:93-100.
2. * Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States : Results from the national comorbidity survey replication. Am J Psychiatry. 2006;163:716-23.
3. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD : A systematic review and metaregression analysis. Am J Psychiatry 2007;164: 942-8. Review.
4. Fayyad J, De Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402-9.
5. * Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self-reports of diagnosed ADHD : A controlled study of 1001 adults in the community. J Clin Psychiatry 2006;67:524-40.
6. Barkley RA. Driving impairments in teens and adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:233-60. Review.
7. Faraone SV. Genetics of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004;27:303-21. Review.
8. * Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1313-23.
9. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993;150:1792-8.
10. * Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2004;65(Suppl.3):3- 7. Review.
11. McGough JJ, Smalley SL, McCracken JT, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder : Findings from multiplex families. Am J Psychiatry 2005;162:1621-7.
12. Arnsten AFT. Stimulants : Therapeutic actions in ADHD. Neuropsychopharmacology 2006;31:2376-83.
13. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry 2005;66:253-9.
14. * Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003;160:1909-18.
15. Levin ED, Conners CK, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 1996;123:55-63.
16. Potter AS, Newhouse PA. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. Pharmacol Biochem Behav 2008;88:407-17.
17. Spencer T, Wilens T, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1995;52: 434-43.
18. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155: 693-5.
19. Paterson R, Douglas C, Hallmayer J, et al. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 1999;33:494-502.
20. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000;10:311-20.
21. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158: 282-8.
22. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2001;58:775-82.
23. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 2001;13:129-34.
24. Tenenbaum S, Paull JC, Sparrow EP, et al. An experimental comparison of pycnogenol and methylphenidate in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). J Atten Disord 2002;6:49-60.
25. Schubiner H, Saules KK, Arfken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10:286-94.
26. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD : Two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-20.
27. Bouffard R, Hechtman L, Minde K, et al. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry 2003;48:546-54.
28. Turner DC, Clark L, Dowson J, et al. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 2004;55:1031-40.
29. Kooij JJ, Burger H, Boonstra AM, et al. Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychol Med 2004;34:973-82.
30. * Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:456-63.
31. Adler LA, Spencer TJ, Milton DR, et al. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/ hyperactivity disorder : An interim analysis. J Clin Psychiatry 2005;66:294-9.
32. Boonstra AM, Kooij JJ, Oosterlaan J, et al. Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD ? J Clin Exp Neuropsychol 2005;27:278-98.
33. Carpentier PJ, de Jong CA, Dijkstra BA, et al. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders. Addiction 2005;100:1868-74.
34. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder : A randomized, placebo-controlled study. Biol Psychiatry 2005;57:793-801.
35. Levin FR, Evans SM, Brooks DJ, et al. Treatment of methadone-maintained patients with adult ADHD : Double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006;81:137-48.
36. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006;59:829-35.
37. Weiss M, Hechtman L ; The Adult ADHD Research Group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problem-focused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 2006;67:611-9.
38. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD : A randomized, controlled trial. CNS Spectr 2006;11:625-39.
39. Levin FR, Evans SM, Brooks DJ, et al. Treatment of cocaine dependent treatment seekers with adult ADHD : Double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007;87:20-9.
40. Spencer TJ, Adler LA, McGough JJ, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007;61:1380-7.
41. Reimherr FW, Williams ED, Strong RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007; 68:93-101.
42. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/ hyperactivity disorder : Results of a double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007;68:268-77.
43. Ramsay JR. Current status of cognitive-behavioral therapy as a psychosocial treatment for adult attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 2007;9:427-33. Review.
44. * Safren SA. Cognitive-behavioral approaches to ADHD treatment in adulthood. J Clin Psychiatry 2006; 67(Suppl. 8):46-50. Review.
45. Kessler RC, Adler LA, Gruber MJ, et al. Validity of the World health organization Adult ADHD self-report scale (ASRS). Screener in a representative sample of health plan members. Int J Methods Psychiatr Res 2007; 16:52-65.